FEBS Letters 2006-04-03

Catalytic folding of the Cepsilon3 domain by its high affinity receptor.

Naomi E Harwood, Nicholas C Price, James M McDonnell

Index: FEBS Lett. 580(8) , 2129-34, (2006)

Full Text: HTML

Abstract

The interaction of immunoglobulin E (IgE) with its cellular receptor FcepsilonRIalpha is a central regulator of allergy. Structural studies have identified the third domain (Cepsilon3) of the constant region of epsilon heavy chain as the receptor binding region. The isolated Cepsilon3 domain is a "molten globule" that becomes structured upon binding of the FcepsilonRIalpha ligand. In this study, fluorescence and nuclear magnetic resonance spectroscopies are used to characterise the role of soluble FcepsilonRIalpha in the folding of the monomeric Cepsilon3 domain of IgE. Soluble FcepsilonRIalpha is shown to display characteristic properties of a catalyst for the folding of Cepsilon3, with the rate of Cepsilon3 folding being dependent on the concentration of the receptor.

Related Compounds

  • 7-azatryptophan

Related Articles:

Phosphorescence and optically detected magnetic resonance characterization of the environments of tryptophan analogues in staphylococcal nuclease, its V66W mutant, and Delta 137-149 fragment.

1998-06-23

[Biochemistry 37(25) , 8954-64, (1998)]

Blue fluorescent amino acids as in vivo building blocks for proteins.

2010-02-15

[ChemBioChem. 11(3) , 305-14, (2010)]

In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.

2004-02-01

[J. Pept. Res. 63(2) , 99-107, (2004)]

Biosynthetic incorporation of tryptophan analogues into staphylococcal nuclease: effect of 5-hydroxytryptophan and 7-azatryptophan on structure and stability.

1997-03-01

[Protein Sci. 6(3) , 689-97, (1997)]

Incorporation of the fluorescent amino acid 7-azatryptophan into the core domain 1-47 of hirudin as a probe of hirudin folding and thrombin recognition.

2004-06-01

[Protein Sci. 13(6) , 1489-502, (2004)]

More Articles...